Glial fibrillary acidic protein (GFAP)

GFAP is a member of the type III intermediate filament that provides support and strength to cells and sustains the cell shape. In 2018, GFAP, together with Ubiquitin C-terminal hydrolase-L1 (UCH-L1), received approval as a biomarker for concussion in adults by the U.S. Food and Drug Administration (FDA). This represented a great milestone in the blood biomarker development for neurological disorders. Furthermore, it can be detected in serum already within the first few hours after a head injury.

Hytest offers several well-characterized monoclonal antibodies that are specific to GFAP and which may be used for the quantification of GFAP in serum, plasma, or CSF.

Learn more:
Cat# 4G25:Glial Fibrillary Acidic Protein, Antibody 
Cat# 8G47: Glial fibrillary acidic protein (GFAP), human, recombinant